The Mina and Everard Goodman Life Sciences Faculty, Bar Ilan University, Ramat Gan, 52900, Israel.
Invest New Drugs. 2012 Jun;30(3):1028-38. doi: 10.1007/s10637-011-9669-6. Epub 2011 Apr 21.
Herein we describe a series of multifunctional 5-aminolevulinic-acid (ALA) prodrugs for photodynamic dependent and independent cancer therapy (PDT). We studied the cell-death mechanisms in glioblastoma U251 cells treated with four ALA-prodrugs: (1) AlaAcBu, that releases ALA, acetaldehyde, and butyric acid; (2) AlaFaBu, that releases ALA, formaldehyde, and butyric acid; (3) AlaFaPi, that releases ALA, formaldehyde and pivalic acid (4) AlaAcPi that releases ALA, acetaldehyde and pivalic acid. We examined the light-activated and dark cell-death mechanisms of the active metabolites released from the prodrugs by unspecific cellular hydrolases. The active moieties accelerated biosynthesis of protoporphyrin IX (PpIX) due to upregulated porphobilinogen deaminase (PBGD) activity. AlaAcBu was found to be the superior prodrug for PDT due to its ability to induce the highest PpIX synthesis. Photo-irradiation of AlaAcBu-treated cells led to dissipation of the mitochondrial membrane potential and reduction in the mitochondria metabolic activities; apoptosis and necrosis. Electron microscopy analyses of these cells revealed mitochondrial and endoplasmic reticulum swelling, membrane blebbing, apoptotic bodies and necrotic cell rupture. The formaldehyde-releasing prodrugs AlaFaBu and AlaFaPi induced low PDT efficacy, moreover sequestering the formaldehyde with semicarbazide resulted in high PpIX synthesis, suggesting that formaldehyde inhibited its synthesis. ALA and AlaAcBu phototherapy resulted in a dramatic accumulation of ubiquitinated proteins due to reduced proteasome activity and expression. In conclusion, the PDT potency of the prodrugs was in the order: AlaAcBu, AlaAcPi > AlaFaBu ≥ ALA > AlaFaPi, and the superiority of AlaAcBu stems from lower molar concentrations of AlaAcBu and lower light intensity needed to activate cell death following PDT.
在此,我们描述了一系列用于光动力依赖和非依赖癌症治疗(PDT)的多功能 5-氨基酮戊酸(ALA)前药。我们研究了用四种 ALA 前药处理神经胶质瘤 U251 细胞后的细胞死亡机制:(1)AlaAcBu,释放 ALA、乙醛和丁酸;(2)AlaFaBu,释放 ALA、甲醛和丁酸;(3)AlaFaPi,释放 ALA、甲醛和特戊酸;(4)AlaAcPi,释放 ALA、乙醛和特戊酸。我们通过非特异性细胞水解酶检查了前药释放的活性代谢物的光激活和暗细胞死亡机制。由于上调的卟胆原脱氨酶(PBGD)活性,这些活性部分加速了原卟啉 IX(PpIX)的生物合成。由于能够诱导最高的 PpIX 合成,AlaAcBu 被发现是 PDT 的优越前药。AlaAcBu 处理细胞的光照射导致线粒体膜电位耗散和线粒体代谢活性降低;细胞凋亡和坏死。这些细胞的电子显微镜分析显示线粒体和内质网肿胀、膜起泡、凋亡小体和坏死细胞破裂。释放甲醛的前药 AlaFaBu 和 AlaFaPi 诱导的 PDT 效果较低,此外,用氨基脲封闭甲醛会导致 PpIX 合成增加,表明甲醛抑制了其合成。ALA 和 AlaAcBu 光疗导致泛素化蛋白的大量积累,这是由于蛋白酶体活性和表达降低所致。总之,前药的 PDT 效力顺序为:AlaAcBu、AlaAcPi>AlaFaBu≥ALA>AlaFaPi,AlaAcBu 的优越性源于其所需的更低摩尔浓度的 AlaAcBu 和更低的光强度来激活 PDT 后的细胞死亡。